On Monday, Arcutis Biotherapeutics Inc (NASDAQ: ARQT) was 4.00% up from the session before settling in for the closing price of $13.01. A 52-week range for ARQT has been $6.99 – $17.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 349.37% over the past five years. When this article was written, the company’s average yearly earnings per share was at 52.13%. With a float of $104.41 million, this company’s outstanding shares have now reached $117.85 million.
Let’s look at the performance matrix of the company that is accounted for 342 employees. In terms of profitability, gross margin is 90.27%, operating margin of -65.33%, and the pretax margin is -70.92%.
Arcutis Biotherapeutics Inc (ARQT) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Arcutis Biotherapeutics Inc stocks. The insider ownership of Arcutis Biotherapeutics Inc is 12.00%, while institutional ownership is 102.27%. The most recent insider transaction that took place on Apr 01 ’25, was worth 151,236. In this transaction Director of this company sold 10,000 shares at a rate of $15.12, taking the stock ownership to the 121,944 shares. Before that another transaction happened on Apr 02 ’25, when Company’s Chief Financial Officer sold 9,600 for $15.80, making the entire transaction worth $151,698. This insider now owns 182,774 shares in total.
Arcutis Biotherapeutics Inc (ARQT) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 52.13% per share during the next fiscal year.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
You can see what Arcutis Biotherapeutics Inc (ARQT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.97. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.17.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.16, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach 0.29 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) saw its 5-day average volume 2.05 million, a negative change from its year-to-date volume of 2.43 million. As of the previous 9 days, the stock’s Stochastic %D was 39.86%. Additionally, its Average True Range was 1.31.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 45.19%, which indicates a significant increase from 29.98% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 93.37% in the past 14 days, which was higher than the 78.81% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.22, while its 200-day Moving Average is $11.78. Nevertheless, the first resistance level for the watch stands at $14.10 in the near term. At $14.66, the stock is likely to face the second major resistance level. The third major resistance level sits at $15.32. If the price goes on to break the first support level at $12.88, it is likely to go to the next support level at $12.22. Assuming the price breaks the second support level, the third support level stands at $11.66.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
There are 118,638K outstanding shares of the company, which has a market capitalization of 1.61 billion. As of now, sales total 196,540 K while income totals -140,040 K. Its latest quarter income was 71,360 K while its last quarter net income were -10,790 K.
